Embracing the failures of biotechnology
Dr. Carl LeBel is the Founder of LeBel Consulting, LLC, that specializes in assisting global biopharmaceutical clients with product development strategies, including discovery, nonclinical, clinical and regulatory activities. He was most recently Chief Scientific Officer at Otonomy Inc. from 2009-2016 where he was responsible for all R&D activities focused on discovery and development of biotherapeutics to treat diseases of the ear, including vertigo, tinnitus, otitis media, and hearing loss. Before Otonomy he was President and CEO at Akesis Pharmaceuticals Inc, a virtual metabolic disease firm, and he held numerous R&D management positions during a 14-year tenure at Amgen Inc. Prior to that he held pharmacology/toxicology positions at Alkermes Inc. and Arthur D. Little Inc.
Dr. LeBel holds a BS in Chemistry from the University of Detroit, a PhD in Biomedical Sciences/Toxicology from Northeastern University, and he was a NIEHS postdoctoral fellow in Community and Environmental Medicine at the University of California, Irvine. He holds memberships in the American Association of Otolaryngology, Association for Research in Otolaryngology, American Association for the Advancement of Science and the Society of Toxicology. Dr. LeBel is also a co-patent holder on hundreds of worldwide patents.
Carl was appointed Entrepreneur in Residence for the Health Sciences Entrepreneurs in April 2017. This is the first EIR for Bouvé College of Health Sciences and the HSE program.